Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- TERN
- Price
- 35.97
- Stock movement down
- -0.36 (-1.31%)
- Company name
- Terns Pharmaceuticals Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 2.37B
- Ent value
- 2.24B
- Price/Sales
- 1795.90
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return (CAGR)
- 341.14%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2025-12-04
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
TERN does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 1795.90 |
| Price to Book | - |
| EV to Sales | 1696.97 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 87.51M |
| EPS (TTM) | -1.03 |
| FCF per share (TTM) | -0.85 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | -108.00K |
| Operating income (TTM) | -108.47M |
| Net income (TTM) | -94.44M |
| EPS (TTM) | -1.03 |
| EPS (1y forward) | -1.22 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 150.70M |
| Net receivables | 0.00 |
| Total current assets | 300.30M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 997.00K |
| Total assets | 301.65M |
| Accounts payable | 2.95M |
| Short/Current long term debt | 1.03M |
| Total current liabilities | 15.39M |
| Total liabilities | 17.59M |
| Shareholder's equity | 284.07M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -77.68M |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -77.68M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -33.24% |
| Return on Assets | -31.31% |
| Return on Invested Capital | -33.19% |
| Cash Return on Invested Capital | -27.30% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 27.22 |
| Daily high | 28.17 |
| Daily low | 26.53 |
| Daily Volume | 3.62M |
| All-time high | 47.09 |
| 1y analyst estimate | 53.56 |
| Beta | -0.24 |
| EPS (TTM) | -1.03 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 31 Mar 2026 |
Downside potential
Loading...
Downside potential data
| TERN | S&P500 | |
| Current price drop from All-time high | -23.61% | -0.89% |
| Highest price drop | -92.66% | -19.00% |
| Date of highest drop | 7 Apr 2025 | 8 Apr 2025 |
| Avg drop from high | -75.33% | -2.49% |
| Avg time to new high | 97 days | 6 days |
| Max time to new high | 278 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
2.37B
Marketcap category
Mid-cap
Description
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity, as well as TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
Employees
59
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page